Orbimed, page-37

And whilst on the subject of Amgen....

Amgen ($AMGN) is building momentum for its new first - of -its - kind cancer fighter, Imlygic.
Two months after getting FDA approval for treating deadly melanoma, it has done the same in Europe, making Imlygic the first immunotherapy oncology drug approved there.

"As the first oncolytic immunotherapy authorized in the European Union, the approval of Imlygic is an important milestone for this new class of drugs, bringing patients with a rare and deadly form of skin cancer a much needed new treatment option," Sean Harper, Amgen's head of R&D, said today in a statement.

The Company will now go through the process of negotiating prices with each of the 31 Countries that adhere to EC approvals. In the U.S., Amgen has said the drug will average $65,000 per patient, but with the caveat that differences in dosing for each patient makes that a ballpark number only..

Amgen bought the treatment in 2011 when it struck a $1 billion deal for Biovex. While initially approved for use against melanoma, the bet is that it will also be effective as a combo therapy against other cancers, a strategy makers of other immunotherapies are following. Amgen is already working to combo Imlygic with Merck's ($MRK) PD-1- blocking Keytruda in melanoma and head and neck cancer. It also has a collaboration with Roche ($RHHBY) to see how Imlygic works in breast and colon cancers when paired with Roche's PD-L1 immuno-oncology candidate.

Interesting... if not incestuous.